Skip to main content
Journal cover image

Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes.

Publication ,  Journal Article
Nasioudis, D; Mastroyannis, SA; Albright, BB; Haggerty, AF; Ko, EM; Latif, NA
Published in: Gynecol Oncol
July 2018

OBJECTIVE: The aim of this study was to investigate the patterns of use and outcomes of adjuvant chemotherapy for patients diagnosed with FIGO stage I ovarian clear cell carcinoma (OCCC). METHODS: A cohort of patients diagnosed between 2004 and 2015 with OCCC was drawn from the National Cancer Database. Those with stage I disease who had primary surgery and underwent systematic lymphadenectomy (defined as at least 10 lymph nodes removed) were selected for further analysis. Factors associated with the administration of adjuvant chemotherapy were investigated with multivariate logistic regression. Overall survival (OS) was evaluated using Kaplan-Meier curves for patients diagnosed between 2004 and 2014, while comparisons were made with the log-rank test. Multivariate Cox analysis was performed to control for possible confounders. RESULTS: A total of 2325 patients met the inclusion criteria. Median age was 55 years. The majority were White (86.6%). Adjuvant chemotherapy was administered to 1839 (79.1%) patients. Hospital type and location, patient age, disease sub-stage, and year of diagnosis were independently associated with the administration of chemotherapy. Patients who received adjuvant chemotherapy (n = 1629) had better OS than those who did not (n = 443), (5-year OS rates 89.2% vs 82.6%, p < 0.001). After controlling for disease sub-stage, age, race, hospital type and medical comorbidities, adjuvant chemotherapy was associated with better overall survival (HR: 0.59, 95% CI: 0.45, 0.78). CONCLUSIONS: Adjuvant chemotherapy could be associated with a survival benefit for patients with stage I OCCC.

Duke Scholars

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

July 2018

Volume

150

Issue

1

Start / End Page

14 / 18

Location

United States

Related Subject Headings

  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasms, Glandular and Epithelial
  • Neoplasm Staging
  • Middle Aged
  • Humans
  • Female
  • Chemotherapy, Adjuvant
  • Carcinoma, Ovarian Epithelial
  • Adenocarcinoma, Clear Cell
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nasioudis, D., Mastroyannis, S. A., Albright, B. B., Haggerty, A. F., Ko, E. M., & Latif, N. A. (2018). Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes. Gynecol Oncol, 150(1), 14–18. https://doi.org/10.1016/j.ygyno.2018.04.567
Nasioudis, Dimitrios, Spyridon A. Mastroyannis, Benjamin B. Albright, Ashley F. Haggerty, Emily M. Ko, and Nawar A. Latif. “Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes.Gynecol Oncol 150, no. 1 (July 2018): 14–18. https://doi.org/10.1016/j.ygyno.2018.04.567.
Nasioudis D, Mastroyannis SA, Albright BB, Haggerty AF, Ko EM, Latif NA. Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes. Gynecol Oncol. 2018 Jul;150(1):14–8.
Nasioudis, Dimitrios, et al. “Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes.Gynecol Oncol, vol. 150, no. 1, July 2018, pp. 14–18. Pubmed, doi:10.1016/j.ygyno.2018.04.567.
Nasioudis D, Mastroyannis SA, Albright BB, Haggerty AF, Ko EM, Latif NA. Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes. Gynecol Oncol. 2018 Jul;150(1):14–18.
Journal cover image

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

July 2018

Volume

150

Issue

1

Start / End Page

14 / 18

Location

United States

Related Subject Headings

  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasms, Glandular and Epithelial
  • Neoplasm Staging
  • Middle Aged
  • Humans
  • Female
  • Chemotherapy, Adjuvant
  • Carcinoma, Ovarian Epithelial
  • Adenocarcinoma, Clear Cell